Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson's Disease

Catalysis SL

Status and phase: Completed; Phase 3

Conditions: Parkinson's Disease

Treatments: Dietary Supplement: VIUSID/ALZER; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01016470

CAT-0916-CU

Details and patient eligibility

About

The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with Parkinson's Disease (PD).

Full description

Periodical measures of the clinical features with UPDRS will be done at the beginning, each three months until two years. Each group will be compare to evaluate.

Enrollment: 100 patients

Sex: All

Ages: 20 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with clinical of PD, with the criteria of Brain Bank of London with early stage.
• Informed consent.

Exclusion criteria

• Presence of another disease not well controlled.
• Patient with atypical features.
• Patient with advanced Parkinson's disease.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups, including a placebo group

B

Placebo Comparator group

Description:

Placebo

Treatment:

Dietary Supplement: Placebo

A

Experimental group

Description:

VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor

Treatment:

Dietary Supplement: VIUSID/ALZER